T cells genetically engineered to express chimeric antigen receptors (CARs) have proven—
and impressive—therapeutic activity in patients with certain subtypes of B cell leukaemia or …

Despite considerable advances in the treatment of multiple myeloma (MM) in the last
decade, a substantial proportion of patients do not respond to current therapies or have a …

Adoptive cell therapy (ACT) has proven to be highly effective in treating blood cancers, but
traditional approaches to ACT are poorly effective in treating solid tumors observed …

Engineering chimeric antigen receptors (CAR) or T cell receptors (TCR) helps create
disease-specific T cells for targeted therapy, but the cost and rigor associated with …

Chimeric antigen receptor (CAR) T-cell therapy is highly effective in the treatment of B-cell
acute lymphoblastic leukemia (ALL) or B-cell lymphoma, providing alternative therapeutic …

The development of high-throughput, data-intensive biomedical research assays and
technologies has created a need for researchers to develop strategies for analyzing …

Chimeric antigen receptor (CAR)-T cells have recently emerged as a powerful therapeutic
approach for the treatment of patients with chemotherapy-refractory or relapsed blood …

Natural killer (NK) cells are a critical component of the innate immune system. Chimeric
antigen receptors (CARs) re-direct NK cells toward tumor cells carrying corresponding …

Although cancer immunotherapy has taken center stage in mainstream oncology inducing
complete and long-lasting tumor regression, only a subset of patients receiving treatment …

T cells engineered with chimeric antigen receptors (CARs) have revolutionized the field of
cell therapy and changed the paradigm of treatment for many patients with relapsed or …